ClinicalTrials.gg
CompletedNCT04924101Updated Aug 13, 2026Results posted

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

A Phase 2 interventional study of Pembrolizumab and MK-4830 in Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 49 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc — 3 open to participants now, 8 under way, 3 of them phase 3. Small Cell Lung Carcinoma · Merck & Co., Inc.

Enrollment
9th of 12
122 · median 280
Started
2021
with 1 other
Phase 2
3 of 12
none open now
Registered
7th of 12
by date

Among the 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc, this one is the 9th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 2, and was the 7th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

3 of the 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
  • Programmed Death-Ligand 2 (PDL2, PD-L2)
  • Pembrolizumab (MK-3475)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC) in need of therapy
  • Has ES-SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition
  • Male participants are eligible to participate if they agree to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. The length of time required to continue for each study intervention is as follows: Lenvatinib (7 days); Etoposide, Cisplatin, or Carboplatin (180 days) and Pembrolizumab, MK-4830, or (no contraception measures); refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent or must agree to use contraception per protocol unless confirmed to be azoospermic
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman/women of (WOCBP) or is a WOCBP and uses a contraceptive method that is highly effective with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention and agrees not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period. The length of time required to continue contraception for each study intervention is as follows: Lenvatinib (30 days), Etoposide, Cisplatin, or Carboplatin (180 days), and Pembrolizumab, MK-4830, or Boserolimab (120 days)
  • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours (urine test) or 72 hours (serum test) before the first dose of study intervention
  • Abstains from breastfeeding during the study intervention period and for at least 120 days after study intervention
  • Has per 1.1 as assessed by local site investigator/radiology and verified by blinded independent central review (BICR)
  • Submits an sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated where such sample exist
  • Has an (ECOG) performance status of 0 or 1 assessed within 7 days before randomization
  • Has adequate organ function within 10 days before the first dose of study intervention
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg with no changes in antihypertensive medications within 1 week before randomization

Exclusion criteria

Exclusion Criteria:

  • Has had major surgery within 3 weeks before first dose of study interventions
  • Has a preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula
  • Has urine protein ≥1 g/24 hours
  • Has a (LVEF) below the institutional (or local laboratory) normal range, as determined by multiple gated acquisition (MUGA) or echocardiogram (ECHO)
  • Prolongation of with Fridericia's correction (QTcF) interval to >480 ms
  • Has cardiovascular disease or major arterial thromboembolic event within 12 months before first dose of study intervention, including Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
  • Has active hemoptysis within 3 weeks before the first dose of study intervention
  • Has gastrointestinal malabsorption or any other condition that might affect oral study intervention absorption
  • Has serious nonhealing wound, ulcer, or bone fracture within 28 days before first dose of study intervention
  • Has any major hemorrhage or venous thromboembolic events within 3 months before the first dose of study intervention. Participants with venous thrombosis diagnosed more than 3 months before the first dose of study intervention must be on stable doses of anticoagulants
  • Has a history of inflammatory bowel disease
  • Has a history of a gastrointestinal perforation within 6 months before the first dose of study intervention
  • Is considered a poor medical risk due to a serious, uncontrolled medical disorder or nonmalignant systemic disease
  • Has received prior therapy with an anti-programmed cell death 1 protein (), anti-programmed cell death ligand 1 (anti-PD-L1), or anti programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received prior treatment (chemotherapy, radiotherapy, or surgical resection) including agents for SCLC
  • Is expected to require any other form of antineoplastic therapy for SCLC, including radiation therapy, while on study
  • Has received a live or within 30 days before the first dose of study intervention
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention
  • Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation. A participant that meets this exclusion criterion but is otherwise deemed eligible for the study may be randomized across the specific intervention groups.
  • Has symptomatic ascites, pleural effusion, or pericardial effusion. A participant who is clinically stable following treatment for these conditions is eligible
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study intervention
  • Has a known additional that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis. Participants with may participate only if they satisfy all of the following: a) Completed treatment at least 14 days before the first dose of study intervention b) Have no evidence of new or enlarging brain metastases confirmed by posttreatment repeat brain imaging performed at least 4 weeks after pretreatment brain imaging, and c) Are neurologically stable without the need for steroids for at least 7 days before the first dose of study intervention as per local site assessment. Participants with untreated brain metastases will be allowed if they are asymptomatic, the investigator determines there is no immediate CNS-specific treatment required, there is no significant surrounding edema, and the brain metastases are of 5 mm or less in size and 3 or fewer in number
  • Has a history of severe reaction to any study intervention and/or any of its
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has a known history of, or active, neurologic paraneoplastic syndrome
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection and/or virus infection or an active infection
  • Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + MK-4830 + Chemotherapy

    Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle (cycle length = 3 weeks) every 3 weeks (Q3W) up to 35 administrations (up to approximately 2 years) or until disease progression (PD) or discontinuation, MK-4830 800 mg IV infusion on Day 1 of each cycle Q3W, up to 35 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m\^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m\^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.

    Biological: Pembrolizumab · Biological: MK-4830 · Drug: Etoposide · Drug: Cisplatin · Drug: Carboplatin

  • Experimental
    Pembrolizumab + Boserolimab + Chemotherapy

    Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle Q3W up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, boserolimab 30 mg IV infusion on Day 1 of each cycle (cycle length = 6 weeks) every 6 weeks (Q6W), up to 18 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m\^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m\^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.

    Biological: Pembrolizumab · Biological: Boserolimab · Drug: Etoposide · Drug: Cisplatin · Drug: Carboplatin

  • Experimental
    Pembrolizumab + Lenvatinib + Chemotherapy

    Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each 3 week cycle (Q3W) up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, lenvatinib 8 mg once daily (QD) orally up to Cycles 1-4 cycles and up to 20 mg QD orally for Cycles 5-31 or until PD or discontinuation; etoposide 100 mg/m\^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m\^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.

    Biological: Pembrolizumab · Drug: Lenvatinib · Drug: Etoposide · Drug: Cisplatin · Drug: Carboplatin

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: KEYTRUDA®, MK-3475, SCH 900475

  • BiologicalMK-4830

    IV infusion

  • BiologicalBoserolimab

    IV infusion

    Also known as: MK-5890

  • Oral capsule

    Also known as: LENVIMA®, KISPLYX®, MK-7902, E7080

  • IV infusion

    Also known as: Etopophos®, Vepesid®, Toposar®, VP-16, Etoposide phosphate

  • IV infusion

    Also known as: Platinol-AQ, Platinol, CDDP

  • IV infusion

    Also known as: Paraplatin, Paraplatin NovaPlus, Carboplatin N+ Novaplus, Carboplatin Novaplus, PremierPro Rx Carboplatin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR is presented.

    Time frame: Up to approximately 43 months

  2. Six-Month Progression-Free Survival (PFS) Rate as Assessed by BICR Per RECIST 1.1

    Six-month PFS rate is defined as the percentage of participants who have survival without documented progressive disease (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first at 6 months after randomization. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS rate at 6 months as assessed by BICR is presented.

    Time frame: At 6 months

Secondary outcomes

  1. Duration of Response (DOR) as Assessed by BICR Per RECIST 1.1

    For participants who demonstrated a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR is presented.

    Time frame: Up to approximately 43 months

  2. Progression-Free Survival (PFS) as Assessed by BICR Per RECIST 1.1

    PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR is presented.

    Time frame: Up to approximately 43 months

  3. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for all participants is presented.

    Time frame: Up to approximately 43 months

  4. Mean Percent Change From Baseline in Tumor Size as Assessed by BICR Per RECIST 1.1

    Tumor size change is defined as the best percent change from baseline in the sum of the diameters of the target lesions as assessed by BICR per RECIST 1.1. The mean best percent change from baseline in tumor size as assessed by BICR per RECIST 1.1 is presented.

    Time frame: Baseline and up to 43 months

  5. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE is presented.

    Time frame: Up to approximately 43 months

  6. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE is presented.

    Time frame: Up to approximately 22 months

  7. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized so that the total score ranges from 0 to 100 for the combined scores. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score is presented.

    Time frame: Baseline, Week 19

07

Results

Posted Jul 1, 2026

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Started434138
Completed000
Not completed434138
Withdrew: (sponsor decision)13109
Withdrew: Withdrawal by subject301
Withdrew: Death273128

Outcome measures

PrimaryObjective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR is presented.

Time frame:
Up to approximately 43 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Percentage of participantsPembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)65.1 (49.1 to 79.0)73.2 (57.1 to 85.8)73.7 (56.9 to 86.6)
PrimarySix-Month Progression-Free Survival (PFS) Rate as Assessed by BICR Per RECIST 1.1

Six-month PFS rate is defined as the percentage of participants who have survival without documented progressive disease (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first at 6 months after randomization. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS rate at 6 months as assessed by BICR is presented.

Time frame:
At 6 months
Reported as:
Number · Percentage of Participants
Six-Month Progression-Free Survival (PFS) Rate as Assessed by BICR Per RECIST 1.1
Percentage of ParticipantsPembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Six-Month Progression-Free Survival (PFS) Rate as Assessed by BICR Per RECIST 1.145.2 (29.9 to 59.4)40.4 (24.9 to 55.3)55.9 (37.8 to 70.6)
SecondaryDuration of Response (DOR) as Assessed by BICR Per RECIST 1.1

For participants who demonstrated a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR is presented.

Time frame:
Up to approximately 43 months
Reported as:
Median · Months
Duration of Response (DOR) as Assessed by BICR Per RECIST 1.1
MonthsPembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Duration of Response (DOR) as Assessed by BICR Per RECIST 1.16.1 (3.9 to 13.9)4.7 (4.2 to 7.1)7.0 (4.4 to 15.7)
SecondaryProgression-Free Survival (PFS) as Assessed by BICR Per RECIST 1.1

PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR is presented.

Time frame:
Up to approximately 43 months
Reported as:
Median · Months
Progression-Free Survival (PFS) as Assessed by BICR Per RECIST 1.1
MonthsPembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Progression-Free Survival (PFS) as Assessed by BICR Per RECIST 1.15.5 (4.2 to 8.3)5.6 (4.2 to 6.7)7.5 (5.5 to 12.7)
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for all participants is presented.

Time frame:
Up to approximately 43 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Overall Survival (OS)18.8 (8.3 to 39.3)16.1 (13.3 to 25.4)15.9 (7.2 to 24.4)
SecondaryMean Percent Change From Baseline in Tumor Size as Assessed by BICR Per RECIST 1.1

Tumor size change is defined as the best percent change from baseline in the sum of the diameters of the target lesions as assessed by BICR per RECIST 1.1. The mean best percent change from baseline in tumor size as assessed by BICR per RECIST 1.1 is presented.

Time frame:
Baseline and up to 43 months
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Tumor Size as Assessed by BICR Per RECIST 1.1
Percent changePembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Mean Percent Change From Baseline in Tumor Size as Assessed by BICR Per RECIST 1.1-57.9 ± 24.9-54.9 ± 25.1-61.6 ± 19.2
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE is presented.

Time frame:
Up to approximately 43 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Number of Participants Who Experienced an Adverse Event (AE)424138
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE is presented.

Time frame:
Up to approximately 22 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Number of Participants Who Discontinued Study Treatment Due to an AE5921
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized so that the total score ranges from 0 to 100 for the combined scores. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score is presented.

Time frame:
Baseline, Week 19
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Scores on a scalePembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + Chemotherapy
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score4.85 (-2.62 to 12.32)1.73 (-5.73 to 9.19)-0.09 (-7.86 to 7.69)

Adverse events

Collected over Up to approximately 43 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-4830 + Pembrolizumab + Etoposide/Platinum28/43 (65.1%)13/43 (30.2%)41/43 (95.3%)
MK-5890 + Pembrolizumab +Etoposide/Platinum31/41 (75.6%)16/41 (39%)41/41 (100%)
Lenvatinib +Pembrolizumab + Etoposide/Platinum28/38 (73.7%)25/38 (65.8%)38/38 (100%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventMK-4830 + Pembrolizumab + Etoposide/PlatinumMK-5890 + Pembrolizumab +Etoposide/PlatinumLenvatinib +Pembrolizumab + Etoposide/Platinum
PneumoniaInfections and infestations3/433/415/38
Febrile neutropeniaBlood and lymphatic system disorders1/431/413/38
SepsisInfections and infestations2/431/413/38
NeutropeniaBlood and lymphatic system disorders1/432/412/38
DeathGeneral disorders0/430/412/38
FatigueGeneral disorders0/431/412/38
COVID-19Infections and infestations0/431/412/38
Aplastic anaemiaBlood and lymphatic system disorders0/430/411/38
Atrial flutterCardiac disorders0/430/411/38
Cardiac arrestCardiac disorders0/430/411/38
Most frequent other events
Showing 10 of 75
Most frequent other events
EventMK-4830 + Pembrolizumab + Etoposide/PlatinumMK-5890 + Pembrolizumab +Etoposide/PlatinumLenvatinib +Pembrolizumab + Etoposide/Platinum
NeutropeniaBlood and lymphatic system disorders30/4329/4130/38
AnaemiaBlood and lymphatic system disorders26/4323/4125/38
ThrombocytopeniaBlood and lymphatic system disorders10/4315/4121/38
ProteinuriaRenal and urinary disorders0/431/4118/38
DiarrhoeaGastrointestinal disorders8/433/4117/38
HypothyroidismEndocrine disorders8/438/4115/38
LeukopeniaBlood and lymphatic system disorders14/4314/417/38
NauseaGastrointestinal disorders14/436/4112/38
HypertensionVascular disorders7/432/4112/38
FatigueGeneral disorders13/437/4111/38

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + ChemotherapyTotal
Mean64.0 ± 8.862.0 ± 9.965.9 ± 10.263.9 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + ChemotherapyTotal
Female913931
Male34282991
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + ChemotherapyTotal
Hispanic or Latino1001
Not Hispanic or Latino414038119
Unknown or Not Reported1102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + MK-4830 + ChemotherapyPembrolizumab + Boserolimab + ChemotherapyPembrolizumab + Lenvatinib + ChemotherapyTotal
American Indian or Alaska Native0000
Asian1062036
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White32351885
More than one race0000
Unknown or Not Reported1001
08

Study locations

49 sites
  • Banner MD Anderson Cancer Center ( Site 0102)
    Gilbert, Arizona 85234, United States
  • University of Colorado Anschutz Medical Campus ( Site 0104)
    Aurora, Colorado 80045, United States
  • Georgia Cancer Specialists ( Site 0106)
    Atlanta, Georgia 30341, United States
  • Parkview Research Center at Parkview Regional Medical Center ( Site 0130)
    Fort Wayne, Indiana 46845, United States
  • Baptist Health Lexington-Research ( Site 0108)
    Lexington, Kentucky 40503, United States
  • MFSMC-HJWCI-Oncology Research ( Site 0128)
    Baltimore, Maryland 21237, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0122)
    Omaha, Nebraska 68130, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0129)
    Omaha, Nebraska 68130, United States
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0114)
    Mineola, New York 11501, United States
  • Memorial Sloan Kettering Cancer Center ( Site 0115)
    New York, New York 10065, United States
  • Cleveland Clinic-Taussig Cancer Center ( Site 0116)
    Cleveland, Ohio 44195, United States
  • UPMC Hillman Cancer Center ( Site 0127)
    Pittsburgh, Pennsylvania 15232, United States
  • St Francis Cancer Center-Research Office ( Site 0117)
    Greenville, South Carolina 29607, United States
  • Virginia Cancer Institute ( Site 0119)
    Richmond, Virginia 23229, United States
  • Klinik Penzing-2. Lungenabteilung ( Site 2101)
    Vienna, State of Vienna 1140, Austria
  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2100)
    Vienna, 1210, Austria
  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2003)
    Hamilton, Ontario L8V 4X2, Canada
  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2005)
    Kingston, Ontario K7L 2V7, Canada
  • St. Marys Hospital Center ( Site 2000)
    Montreal, Quebec H3T 1M5, Canada
  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 2800)
    Szolnok, Jász-Nagykun-Szolnok 5004, Hungary
  • Országos Korányi Pulmonológiai Intézet-XIV. Tüdöbelgyógyászat ( Site 2806)
    Budapest, Pest County 1121, Hungary
  • Torokbalint Tudogyogyintezet-Onkopulmonologiai Jarobeteg Centrum ( Site 2801)
    Törökbálint, Pest County 2045, Hungary
  • Zala Megyei Szent Rafael Kórház-Pulmonológia ( Site 2805)
    Zalaegerszeg, Zala County 8900, Hungary
  • Semmelweis University-Pulmonológiai Klinika ( Site 2802)
    Budapest, 1083, Hungary
  • Rambam Health Care Campus-Oncology ( Site 2600)
    Haifa, 3109601, Israel
  • Shaare Zedek Medical Center ( Site 2602)
    Jerusalem, 9103102, Israel
  • Meir Medical Center ( Site 2601)
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center-Oncology ( Site 2604)
    Petah Tikva, 4941492, Israel
  • Sheba Medical Center-ONCOLOGY ( Site 2603)
    Ramat Gan, 5262100, Israel
  • Ospedale San Raffaele-Oncologia Medica ( Site 2303)
    Milan, Lombardy 20132, Italy
  • ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 2300)
    Siena, Tuscany 53100, Italy
  • Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 2304)
    Milan, 20141, Italy
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Samodzielny Publiczny Zespó Grulicy i Chorób Puc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemi
    Olsztyn, Warmian-Masurian Voivodeship 10-357, Poland
  • Krasnoyarsk Regional Oncology Dispensary, Named after Krizhanovsky ( Site 2708)
    Krasnoyarsk, Krasnoyarsk Krai 660133, Russia
  • GBUZ "SPb CRPCstmc(o)" ( Site 2705)
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 2704)
    Saint Petersburg, 197758, Russia
  • Seoul National University Bundang Hospital ( Site 1104)
    Seongnam, Kyonggi-do 13620, South Korea
  • The Catholic University Of Korea St. Vincent's Hospital ( Site 1106)
    Suwon, Kyonggi-do 16247, South Korea
  • Chungbuk National University Hospital ( Site 1107)
    Cheongju-si, North Chungcheong 28644, South Korea
  • Seoul National University Hospital ( Site 1101)
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1105)
    Seoul, 03722, South Korea
  • Asan Medical Center-Department of Oncology ( Site 1103)
    Seoul, 05505, South Korea
  • Samsung Medical Center ( Site 1100)
    Seoul, 06351, South Korea
  • Instituto Catalan de Oncologia - Hospital Duran i Reynals ( Site 2403)
    L'Hospitalet de Llobregat, Catalonia 08908, Spain
  • Hospital Insular de Gran Canaria ( Site 2402)
    Las Palmas de Gran Canaria, Las Palmas 35001, Spain
  • Hospital Universitari Vall d'Hebron-Oncology ( Site 2401)
    Barcelona, 08035, Spain
  • Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 2502)
    Sankt Gallen, Canton of St. Gallen 9007, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jun 2025, 47 months.

Results were first posted in Jul 2026, 1 year after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 47 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2021
First posted
Jun 11, 2021
StartActual
Jul 15, 2021
Primary completionActual
Jun 23, 2025
CompletionActual
Jun 23, 2025
Results first posted
Jul 1, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04924101
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Jul 15, 2021
Primary completion
Jun 23, 2025
Completion
Jun 23, 2025
Results posted
Jul 1, 2026
Last update
Aug 13, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-ILT4 Monoclonal Antibody MK-4830 · Boserolimab · Lenvatinib

Start the discussion